UroGen Pharma Ltd. (URGN)
36.83
-0.15
(-0.41%)
USD |
NASDAQ |
Oct 09, 16:00
36.83
0.00 (0.00%)
After-Hours: 20:00
UroGen Pharma Net Income (Quarterly) : -14.35M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -14.35M |
| March 31, 2026 | -23.57M |
| December 31, 2025 | -26.36M |
| September 30, 2025 | -33.35M |
| June 30, 2025 | -49.94M |
| March 31, 2025 | -43.84M |
| December 31, 2024 | -37.51M |
| September 30, 2024 | -23.67M |
| June 30, 2024 | -33.40M |
| March 31, 2024 | -32.29M |
| December 31, 2023 | -26.02M |
| September 30, 2023 | -21.88M |
| June 30, 2023 | -24.14M |
| March 31, 2023 | -30.21M |
| December 31, 2022 | -28.25M |
| September 30, 2022 | -25.83M |
| June 30, 2022 | -26.69M |
| March 31, 2022 | -28.39M |
| December 31, 2021 | -28.45M |
| Date | Value |
|---|---|
| September 30, 2021 | -30.21M |
| June 30, 2021 | -26.22M |
| March 31, 2021 | -25.94M |
| December 31, 2020 | -30.53M |
| September 30, 2020 | -28.82M |
| June 30, 2020 | -31.35M |
| March 31, 2020 | -37.79M |
| December 31, 2019 | -38.97M |
| September 30, 2019 | -22.25M |
| June 30, 2019 | -22.48M |
| March 31, 2019 | -21.44M |
| December 31, 2018 | -23.72M |
| September 30, 2018 | -20.53M |
| June 30, 2018 | -18.03M |
| March 31, 2018 | -13.38M |
| December 31, 2017 | -10.07M |
| September 30, 2017 | -0.298M |
| June 30, 2017 | -6.199M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Xencor, Inc. | -21.73M |
| MeiraGTx Holdings Plc | 160.67M |
| Insmed, Inc. | -13.24M |
| Ironwood Pharmaceuticals, Inc. | 51.29M |
| Viking Therapeutics, Inc. | -128.02M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 72.46M |
| Total Expenses (Quarterly) | 86.81M |
| EPS Diluted (Quarterly) | -0.2848 |
| Enterprise Value | 1.887B |
| Gross Profit Margin (Quarterly) | 90.93% |
| Profit Margin (Quarterly) | -19.81% |
| Earnings Yield | -5.41% |
| Normalized Earnings Yield | -5.414 |